Kathleen Hershon, MD
Psychiatry · Northampton, MANPI 1114366507
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $29,320 of the $46,499 with a category attached, or 63.1%. 12 manufacturers reported payments, led by Johnson & Johnson at 43.5% of the total. 2025 is the largest year on record at $42,493, more than ten times the $51 reported in 2019. Among psychiatry clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 267 payments — averaging $174.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$20K
- Teva Pharmaceuticals USA, Inc.$13K
- E.r. Squibb & Sons, L.L.C.$11K
- Neurocrine Biosciences, Inc.$720
- Otsuka America Pharmaceutical, Inc.$536
- Alkermes, Inc.$424
- plus $863 from 6 others
What the payments were for
- Consulting fees$7,01515%
- Speaking & faculty fees$29,32063%
- Travel & lodging$3,6858%
- Food & beverage$6,21013%
- Education$2691%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 43 | $20,204 |
| Teva Pharmaceuticals USA, Inc. | 69 | $12,665 |
| E.r. Squibb & Sons, L.L.C. | 19 | $11,087 |
| Neurocrine Biosciences, Inc. | 32 | $720 |
| Otsuka America Pharmaceutical, Inc. | 36 | $536 |
| Alkermes, Inc. | 22 | $424 |
| AbbVie | 19 | $362 |
| Vanda Pharmaceuticals Inc. | 16 | $186 |
| Axsome Therapeutics, Inc. | 5 | $133 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $108 |
| Astellas Pharma US Inc | 1 | $51 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$46,499 in reported general payments places this provider in the 95th percentile of 1,431 psychiatry providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SpravatoEsketamine Hcl | 228 | $274,176 |
| Invega SustennaPaliperidone Palmitate | 38 | $138,291 |
| Austedo XrDeutetrabenazine | 12 | $96,085 |
| AustedoDeutetrabenazine | 28 | $79,919 |
| VraylarCariprazine Hcl | 41 | $57,712 |
| VyvanseLisdexamfetamine Dimesylate | 34 | $16,412 |
| Aripiprazole | 201 | $11,925 |
| DepakoteDivalproex Sodium | 13 | $10,943 |
| Clozapine | 211 | $6,505 |
| Olanzapine | 181 | $5,015 |
| RisperdalRisperidone | 13 | $4,983 |
| Trazodone Hcl | 295 | $4,398 |
| Divalproex Sodium ErDivalproex Sodium | 108 | $4,320 |
| Quetiapine Fumarate | 243 | $4,221 |
| Oxcarbazepine | 98 | $4,184 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonSpravato, Invega Sustenna, Risperdal | $20,204 | $417,451279 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr, Austedo | $12,665 | $176,00440 claims |
| AbbVieVraylar | $362 | $57,71241 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $22 | $16,41234 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,431 psychiatry providers in Massachusetts.
Other psychiatry in Northampton
- Theresa CerulliNorth Andover$724K
- Andrew AldridgeMedford$407K
- Amjad BahnassiWorcester$352K
- Ximena Sanchez-SamperBoston$258K
- Robert AlexanderBelmont$170K
- George PapakostasBoston$170K
- Xiangyang LiMilford$166K
- Ernesto ZilberbergNorth Andover$141K
- Maurizio FavaBoston$120K
- Craig SurmanCambridge$111K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.